Browse Category

Financial Reports News 10 November 2025 - 17 November 2025

Light & Wonder (LNW) Completes Nasdaq Delisting as ASX CDI Listing, New ESPP and Governance Filings Go Live – 13 November 2025

Light & Wonder (LNW) Completes Nasdaq Delisting as ASX CDI Listing, New ESPP and Governance Filings Go Live – 13 November 2025

Light & Wonder, Inc. has officially wrapped up its U.S. primary listing era. The gaming and iGaming group has now completed its long‑flagged Nasdaq delisting, shifted its capital‑markets home to the Australian Securities Exchange (ASX), refreshed its employee stock purchase
Polestar (PSNYW) today: reverse stock split plan, wider Q3 loss, 9‑month revenue +49% — what it means for warrant holders (Nov 12, 2025)

Polestar (PSNYW) today: reverse stock split plan, wider Q3 loss, 9‑month revenue +49% — what it means for warrant holders (Nov 12, 2025)

What happened today (Nov 12, 2025) Polestar Automotive reported third‑quarter results and said it will execute a reverse stock split to address Nasdaq’s minimum bid requirement. Shares fell in early U.S. trading after the update, with Reuters noting an intraday
Leap Therapeutics (LPTX) Rebrands as “Cypherpunk,” Buys $50M in Zcash; Ticker to Change to CYPH on Nov. 13 — Q3 Results and New $200M ATM Filed (Nov. 12, 2025)

Leap Therapeutics (LPTX) Rebrands as “Cypherpunk,” Buys $50M in Zcash; Ticker to Change to CYPH on Nov. 13 — Q3 Results and New $200M ATM Filed (Nov. 12, 2025)

Leap Therapeutics, Inc. (Nasdaq: LPTX) unveiled a sweeping strategic pivot today: the oncology company is rebranding as Cypherpunk Technologies Inc., has already purchased ~$50 million of Zcash (ZEC) for a new digital‑asset treasury strategy, and will switch its Nasdaq ticker
InflaRx (IFRX) pops on positive INF904 Phase 2a results in HS & CSU; Q3 filing shows €44.4M liquidity and runway into 2027 — Nov 10, 2025

InflaRx (IFRX) pops on positive INF904 Phase 2a results in HS & CSU; Q3 filing shows €44.4M liquidity and runway into 2027 — Nov 10, 2025

InflaRx N.V. (NASDAQ: IFRX) surged into today’s session after unveiling topline Phase 2a data for its oral C5aR inhibitor INF904 in hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU), alongside filing its third‑quarter Form 6‑K showing €44.4 million of available
1 5 6 7 8
Go toTop